Top of this page
Skip navigation, go straight to the content
In the European Union, Vimpat® (lacosamide) (film-coated tablets, syrup and solution for infusion) is indicated as monotherapy and adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 4 years of age with epilepsy.
Vimpat® solution for infusion may be used when oral administration is temporarily not feasible.
In the US, Vimpat® (lacosamide) CV is indicated
In the U.S., Vimpat® is available as oral tablets, oral solution and injection.
For availability of Vimpat® in other countries, please consult our local websites.